Literature DB >> 1859758

Pharmacokinetic model driven infusion of propofol in children.

B Marsh1, M White, N Morton, G N Kenny.   

Abstract

A computer controlled infusion device for propofol was used to induce and maintain general anaesthesia in 20 children undergoing minor surgical procedures. The device was programmed with an adult pharmacokinetic model for propofol. During and after anaesthesia, blood samples were taken for measurement of propofol concentrations and it was found that the values obtained were systematically overpredicted by the delivery system algorithm. New pharmacokinetic microconstants were derived from our data which reflected more accurately the elimination and distribution of propofol in a prospective study involving another 10 children.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1859758     DOI: 10.1093/bja/67.1.41

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  168 in total

1.  Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients.

Authors:  Simone van Kralingen; Jeroen Diepstraten; Mariska Y M Peeters; Vera H M Deneer; Bert van Ramshorst; René J Wiezer; Eric P A van Dongen; Meindert Danhof; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2011-11-01       Impact factor: 6.447

2.  A two-compartment effect site model describes the bispectral index after different rates of propofol infusion.

Authors:  Marcus A Björnsson; Ake Norberg; Sigridur Kalman; Mats O Karlsson; Ulrika S H Simonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-04-23       Impact factor: 2.745

3.  The range of values of "variable alpha" when predicting plasma concentrations and/or effect site concentrations of remifentanil is huge.

Authors:  Takayuki Kunisawa; Michio Nagashima; Akihiro Suzuki; Osamu Takahata; Hiroshi Iwasaki
Journal:  J Anesth       Date:  2010-05-28       Impact factor: 2.078

4.  A bodyweight-dependent allometric exponent for scaling clearance across the human life-span.

Authors:  Chenguang Wang; Mariska Y M Peeters; Karel Allegaert; Heleen J Blussé van Oud-Alblas; Elke H J Krekels; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe
Journal:  Pharm Res       Date:  2012-06       Impact factor: 4.200

5.  Connectivity changes underlying spectral EEG changes during propofol-induced loss of consciousness.

Authors:  Mélanie Boly; Rosalyn Moran; Michael Murphy; Pierre Boveroux; Marie-Aurélie Bruno; Quentin Noirhomme; Didier Ledoux; Vincent Bonhomme; Jean-François Brichant; Giulio Tononi; Steven Laureys; Karl Friston
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

Review 6.  Target-controlled infusion systems: role in anaesthesia and analgesia.

Authors:  M C van den Nieuwenhuyzen; F H Engbers; J Vuyk; A G Burm
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

7.  Correlation of Narcotrend Index, entropy measures, and spectral parameters with calculated propofol effect-site concentrations during induction of propofol-remifentanil anaesthesia.

Authors:  Ulrich Grouven; Frank A Beger; Barbara Schultz; Arthur Schultz
Journal:  J Clin Monit Comput       Date:  2004-08       Impact factor: 2.502

8.  The correlation of the bispectral index with propofol effect site concentrations is not altered by epochs indicated as artefact-loaded by narcotrend.

Authors:  Richard K Ellerkmann; Sascha Kreuer; Wolfram Wilhelm; Ingobert Wenningmann; Heiko Roepcke; Andreas Hoeft; Jörgen Bruhn
Journal:  J Clin Monit Comput       Date:  2004-08       Impact factor: 2.502

9.  Predictive performance of 'Diprifusor' TCI system in patients during upper abdominal surgery under propofol/fentanyl anesthesia.

Authors:  Yu-hong Li; Jian-hong Xu; Jian-jun Yang; Jie Tian; Jian-guo Xu
Journal:  J Zhejiang Univ Sci B       Date:  2005-01       Impact factor: 3.066

Review 10.  [Dexmedetomidine. Pharmacokinetics and pharmacodynamics].

Authors:  H Ihmsen; T I Saari
Journal:  Anaesthesist       Date:  2012-12       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.